- Home
- WIA vs PLRX Comparison
WIA vs PLRX Comparison
Compare WIA & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIA
- PLRX
- Stock Information
- Founded
- WIA 2003
- PLRX 2015
- Country
- WIA United States
- PLRX United States
- Employees
- WIA N/A
- PLRX N/A
- Industry
- WIA Trusts Except Educational Religious and Charitable
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- WIA Finance
- PLRX Health Care
- Exchange
- WIA Nasdaq
- PLRX Nasdaq
- Market Cap
- WIA 191.5M
- PLRX 165.5M
- IPO Year
- WIA N/A
- PLRX 2020
- Fundamental
- Price
- WIA $8.21
- PLRX $3.08
- Analyst Decision
- WIA
- PLRX Buy
- Analyst Count
- WIA 0
- PLRX 10
- Target Price
- WIA N/A
- PLRX $14.86
- AVG Volume (30 Days)
- WIA 39.2K
- PLRX 3.4M
- Earning Date
- WIA 01-01-0001
- PLRX 03-07-2025
- Dividend Yield
- WIA 12.29%
- PLRX N/A
- EPS Growth
- WIA N/A
- PLRX N/A
- EPS
- WIA N/A
- PLRX N/A
- Revenue
- WIA N/A
- PLRX N/A
- Revenue This Year
- WIA N/A
- PLRX N/A
- Revenue Next Year
- WIA N/A
- PLRX N/A
- P/E Ratio
- WIA N/A
- PLRX N/A
- Revenue Growth
- WIA N/A
- PLRX N/A
- 52 Week Low
- WIA $7.56
- PLRX $2.43
- 52 Week High
- WIA $8.91
- PLRX $18.00
- Technical
- Relative Strength Index (RSI)
- WIA 55.39
- PLRX 22.51
- Support Level
- WIA $8.02
- PLRX $2.92
- Resistance Level
- WIA $8.35
- PLRX $3.16
- Average True Range (ATR)
- WIA 0.10
- PLRX 0.85
- MACD
- WIA 0.00
- PLRX -0.39
- Stochastic Oscillator
- WIA 57.58
- PLRX 6.22
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.